ANCA-associated vasculitis (AAV)
Clinical trials for ANCA-associated vasculitis (AAV) explained in plain language.
Never miss a new study
Get alerted when new ANCA-associated vasculitis (AAV) trials appear
Sign up with your email to follow new studies for ANCA-associated vasculitis (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a One-Time immune cell treatment tame severe vasculitis?
Disease control OngoingThis Phase 2 trial tests a one-time infusion of rapcabtagene autoleucel, a CAR-T cell therapy made from a patient's own immune cells, against standard treatments for severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). About 126 adults aged 18-7…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control By invitation onlyThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase 1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC